id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_ezannhvygnhrlkdq6vuhetbbwa	Sanjay Kaul	Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?	2016	3	.pdf	application/pdf	2136	233	57	Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? failure despite the fact that mortality was not prespecified as a primary or a secondary end point in the pivotal trials.5 Finally, the P values for both all-cause and cardiovascular mortality are robust enough to preserve type 1 or and cardiovascular mortality, but not 3-point MACE (the evidence for 3-point MACE and mortality results in EMPAREG OUTCOME are shown in Table 1. Evaluating Strength of Evidence of cardiovascular Outcomes in EMPA-rEG OUTcOME Using Bayes Factor EMPA-REG Outcome indicates BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HR, hazard ratio; and confidence from the trial results so far is that mortality benefit is unlikely to be mediated by favorable but very modest magnitude of mortality benefit in EMPA-REG OUTCOME cardiovascular outcomes, and mortality in type 2 diabetes.	./cache/work_ezannhvygnhrlkdq6vuhetbbwa.pdf	./txt/work_ezannhvygnhrlkdq6vuhetbbwa.txt